-
Launched a full-scene, one-stop Chinese New Year special service, Ping An of China accompanies you to celebrate the New Year with "Peace"
Time of Update: 2023-02-01
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
JP Morgan 2023: Agilent to expand production of therapeutic nucleic acids, with outstanding performance in China
Time of Update: 2023-02-01
In fiscal 2022, the revenue from the company's existing operations exceeded $300 million.
In fiscal 2022, the revenue from the company's existing operations exceeded $300 million.
In fiscal 2022, the revenue from the company's existing operations exceeded $300 million.
-
Sinovac completed the first patient enrollment in the phase I clinical trial of interferon inhalation solution for children
Time of Update: 2023-02-01
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
JP Morgan 2023: PacBio reveals more details about the new sequencer
Time of Update: 2023-02-01
"Fourth-quarter revenue was below our expectations, in part because Revio replaced most of the Sequel IIe's demand," Henry said.
"Fourth-quarter revenue was below our expectations, in part because Revio replaced most of the Sequel IIe's demand," Henry said.
-
The world's first diabetic patient to get rid of exogenous insulin by porcine islet transplantation
Time of Update: 2023-02-01
The Third Xiangya Hospital of Central South University revealed on the 12th that after the hospital's re-examination, the world's first porcine islet transplant patient with type 2 diabetes mellitus had normal glycated hemoglobin, postprandial blood glucose and kidney function, and achieved complete detachment of exogenous insulin.
-
Sartorius and RoosterBio advance downstream purification of exosome production
Time of Update: 2023-02-01
Through this collaboration, Sartorius and RoosterBio will collectively provide best-in-class solutions and expertise for human mesenchymal stem cell/stromal cell (hMSC)-based exosome production platforms that deliver industry-leading yield, purity, and potency.
-
The State Food and Drug Administration conditionally approved the marketing of mobosetinib succinate capsules
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Recently, the State Medical Products Administration (NMPA) conditionally approved the listing of Mobosetinib succinate capsules (trade name: ENVIRIX/EXKIVITY) declared by Takeda Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];Recently, the State Medical Products Administration (NMPA) conditionally approved the listing of Mobosetinib succinate capsules (trade name: ENVIRIX/EXKIVITY) declared by Takeda Pharmaceutical Co.
-
JP Morgan 2023: 10x Genomics announces three new developments across three platforms
Time of Update: 2023-02-01
Spatial upgrades The Visium spatial genomics platform helps researchers "see how molecules in a sample are arranged," Saxonov said.
Spatial upgrades The Visium spatial genomics platform helps researchers "see how molecules in a sample are arranged," Saxonov said.
-
Multidisciplinary doctors worked together The 2.6 kg anus-free baby successfully completed the transverse colostomy
Time of Update: 2023-02-01
Rectal and malformations require prompt surgery The United Family Healthcare Fund treats sick abandoned babies every year Zhang Qinming, director of pediatric surgery and emergency director of UFH Jingbei Women's and Children's Hospital, said that 40% to 50% of children with "congenital rectal and malformations", including absence and stenosis, will have urinary diseases and heart malformations.
-
It's time for the lottery! The lucky draw list for the 2022 Innovative Product Selection Event was announced
Time of Update: 2023-02-01
Since its launch in December, the 2022 Life Science Top Ten Innovative Products Selection Event has attracted the attention of readers. Many enthusiastic readers actively participated in the event an
-
Guangzhou InnoCare was recognized as "Guangdong Province 2022 Technologically Advanced Service Enterprise" and other titles
Time of Update: 2023-02-01
About InnoCare InnoCare (SSE: 688428; HKEx code: 09969) is a commercial-stage biomedical high-tech company focusing on the development of a class of new drugs in the field of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma, solid tumors and autoimmune diseases.
-
Merck's PD-1 inhibitor KEYTRUDA (R) was approved for a new indication for the treatment of triple-negative breast cancer in China
Time of Update: 2023-01-06
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Bect Medical brought a number of debut exhibits to the 5th CIIE, and the innovation ecology helped healthy China
Time of Update: 2023-01-06
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
The 2022 academic annual meeting of the Hematology Professional Committee of the China Association of Non-public Medical Institutions was successfully held
Time of Update: 2023-01-06
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Abbott and authoritative media release "2022 Diabetes Nutrition Cognitive Consumer Insights"
Time of Update: 2023-01-06
com Health Nutrition and Wellness Business Unit As one of the major chronic diseases, publicity and education, diet control, exercise therapy, drug treatment and blood glucose monitoring are the "five carriages" of diabetes prevention and management, and diet, as a component closely related to daily life, will directly affect blood sugar control and disease development, and is an important concern of diabetic patients 。 Yang Ye, vice president of JD.
-
Fujifilm participated in the 14th East-West Small Animal Clinical Veterinarian Conference 2022
Time of Update: 2023-01-06
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Shanghai Hehuang Pharmaceutical was awarded the "National Harmonious Labor Relations Creation Model Enterprise"
Time of Update: 2023-01-06
62em; font-family:"Arial"; color:black; margin:0in; } SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- On the afternoon of November 9, Lu Ying, director of the Human Resources and Social Security Bureau of Fengxian District, Shanghai, and Lu Baowen, deputy director of the bureau, came to the R&D and production base of Shanghai Hehuang Pharmaceutical Fengpu and sent the bronze medal and honor book of "National Harmonious Labor Relations Creation Demonstration Enterprise" to the company.
-
Jew Therapeutics announced that its cellular immunotherapy drugs have successfully benefited 300 patients
Time of Update: 2023-01-06
WuXi JW has successfully built a world-class cell immunotherapy technology and product development platform, as well as a product pipeline covering hematological and solid tumors, and has carried out 9 clinical studies for hematological and solid tumors.
-
Jew Therapeutics announced that its cellular immunotherapy drugs have successfully benefited 300 patients
Time of Update: 2023-01-06
WuXi JW has successfully built a world-class cell immunotherapy technology and product development platform, as well as a product pipeline covering hematological and solid tumors, and has carried out 9 clinical studies for hematological and solid tumors.
-
The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets
Time of Update: 2023-01-06
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
